Hematopoietic stem cell transplantation for acute myeloid leukemia: Brazilian Society of Cell Therapy and Bone Marrow Transplantation Consensus
DOI:
https://doi.org/10.46765/2675-374X.2025v7n1e373Keywords:
Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, BrazilAbstract
This document updates the 2023 Brazilian Society of Cell Therapy and Bone Marrow Transplantation (SBTMO) consensus on allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML), incorporating the 2022 and 2024 European LeukemiaNet (ELN) risk classifications, the 2025 ELN-DAVID measurable residual disease (MRD) recommendations, recent induction trials, and the 2025 European Society for Blood and Marrow Transplantation (EBMT) transplant indications. MRD monitoring, assessed by quantitative polymerase chain reaaction, next-generation sequencing, or multiparameter flow cytometry, now guides transplant timing alongside ELN risk category, refining decisions in intermediate-risk patients and informing pre- and post-transplant management. Allogeneic HSCT remains indicated for adverse-risk AML and second complete remission regardless of MRD status, while favorable-risk patients generally avoid transplant unless MRD persists after consolidation. For elderly patients, chronological age alone should not exclude HSCT candidacy; comprehensive geriatric assessment and alternative donor sources have expanded access, supported by Brazilian regulatory changes raising the eligibility age to 75. Conditioning strategy, graft-versus-host disease prophylaxis with post-transplant cyclophosphamide, stem cell source selection, and donor immunogenetic screening are addressed, alongside emerging post-transplant maintenance therapies for high-risk molecular subgroups. Novel cellular therapies— CAR-T and CAR-NK cells—remain investigational, limited by antigen escape and short persistence, requiring consolidation with allogeneic HSCT. This consensus provides evidence-graded recommendations to standardize transplant decisionmaking for AML across Brazilian centers, reflecting the rapidly evolving therapeutic and diagnostic landscape.
References
1. Silla LMR, Ikoma-Colturato MRV, Funke VA, Pitombeira BSGS, Paton EJA, Hamerschlak N, Arantes A, Astigarraga C, Barroso KSN, Beltrame MP, Bettarelo G, Campregher P, Furtado FM, Souto EX, Torres MA, Duarte FB. Hematopoietic stem cell transplantation for acute myeloid leukemia: consensus update. JBMTCT. 2023;4(1):14-8. https://doi.org/10.46765/2675-374X.2023v4n1p184
2. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood. 2022;140(12):1345-77.
3. Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169-73.
4. Sanz J, Bug G, Ciceri F, Craddock C, Dillon R, Esteve J, Porta MGD, Heuser M, de Leeuw DC, Nagler A, Onida F, Roboz GJ, Ruggeri A, Sánchez-Ortega I, Srour M, Yakoub-Agha I, Buccisano F. Measurable residual diseaseguided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26(11):e586-96. https://doi.org/10.1016/s1470-2045(25)00426-7
5. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and venetoclax in previously untreated AML (VIALE-A). N Engl J Med. 2020;383(7):617-29.
6. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J. 2021 Update on MRD in AML: A Consensus Document from the ELN MRD Working Party. Blood. 2021;138(26):2753-67.
7. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7): 1703-19. https://doi.org/10.1038/s41375-022-01613-1
8. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International consensus classification of myeloid neoplasms and acute leukemias: integrating genetic, clinical, and morphologic information. Blood. 2022;140(11):1200-28. https://doi.org/10.1182/blood.2022015850
9. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. https://doi.org/10.1182/blood-2016-03-643544
10. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lowerintensity therapy. Blood Adv. 2024;8(20):5297-305. https://doi.org/10.1182/bloodadvances.2024013685
11. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4): 615-24. https://doi.org/10.1002/ajh.27246
12. Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bücklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147(11):1147-67. https://doi.org/10.1182/blood.2025031480
13. Venditti A, Piciocchi A, Candoni A, Melillo L, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foà R, Alati C, La Sala E, Fazi P, Vignetti M, Maurillo L, Buccisano F, Del Principe MI, Irno-Consalvo M, Ottone T, Lavorgna S, Voso MT, Lo-Coco F, Arcese W, Amadori S. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935-45. https://doi.org/10.1182/blood.2018886960
14. Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021;5(4):1110-21. https://doi.org/10.1182/bloodadvances.2020003855
15. Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica. 2023;108(10):2794-8. https://doi.org/10.3324/haematol.2022.282639
16. Han L, Li Y, Wu J, Peng J, Han X, Zhao H, He C, Li Y, Wang W, Zhang M, Li Y, Sun H, Cao H, Sang L, Jiang Z, Yu J. Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1. Int J Hematol. 2022;116(6):892-901. https://doi.org/10.1007/s12185-022-03441-6
17. Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 2024;143(19):1931-6. https://doi.org/10.1182/blood.2023023096
18. Appelbaum FR. Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. Best Pract Res Clin Haematol. 2018;31(4): 405-9. https://doi.org/10.1016/j.beha.2018.09.009
19. Versluis J, Kalin B, Zeijlemaker W, Passweg J, Graux C, Manz MG, Vekemans MC, Biemond BJ, Legdeur MJC, Kooy MVM, de Weerdt O, Wijermans PW, Hoogendoorn M, Bargetzi MJ, Kuball J, Schouten HC, van der Velden VHJ, Janssen JJWM, Pabst T, Lowenberg B, Jongen-Lavrencic M, Schuurhuis GJ, Ossenkoppele G, Cornelissen JJ. Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission. JCO Precis Oncol. 2017;1:1-13. https://doi.org/10.1200/po.17.00078
20. Shaffer BC, Kebriaei P, Lima M, Jimenez AMJ. Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting PreMEASURE to clinical practice. BMT. 2025;60:128-34. https://doi.org/10.1038/s41409-024-02481-2
21. Aitken MJL, Ravandi F, Patel KP, Short NJ. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol. 2021;14(1):137. https://doi.org/10.1186/s13045-021-01148-5
22. Gang M, Othus M, Walter RB. Significance of measurable residual disease in patients undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Cells. 2025;14(4):290. https://doi.org/10.3390/cells14040290
23. Geramita E, Hou JZ, Shlomchik WD, Ito S. Maintenance strategies for relapse prevention and treatment. Hematology. 2024;2024(1):635-43. https://doi.org/10.1182/hematology.2024000589
24. Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biol Blood Marrow Transplant. 2018;24(7):1514-20. https://doi.org/10.1016/j.bbmt.2018.02.003
25. Wienecke CP, Heida B, Venturini L, Gabdoulline R, Krüger K, Teich K, Büttner K, Wichmann M, Puppe W, Neziri B, Reuter M, Dammann E, Stadler M, Ganser A, Hambach L, Thol F, Heuser M. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Blood. 2024;144(3): 296-307. https://doi.org/10.1182/blood.2023022697
26. Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood. 2020;135(19):1639-49. https://doi.org/10.1182/blood.2019003566
27. Tavares RCB, Pelegrina PRD, Breviglieri CNM, Rodrigues ALM, Zamperlini G, Sousa AM, Horn PRCB, Darrigo Jr LG, Daudt L. Management of pediatric acute leukemias relapse after hematopoietic cell transplantation. J Bone Marrow Transplant Cell Ther. 2025;6(1):e285. https://doi.org/10.46765/2675-374X.2025v6n1e285
28. 2 Wildes TM, Stirewalt DL, Medeiros B, Hurria A. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw. 2014;12(1):128-36. https://doi.org/10.6004/jnccn.2014.0010
29. Gratwohl A. The EBMT risk score. Bone Marrow Transplant. 2012;47(6):749-56. https://doi.org/10.1038/bmt.2011.110
30. Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, Hazenberg MD, Kalwak K, Kenyon M, Mekelenkamp H, Neven B, Pedrazzoli P, Peric Z, Risitano AM, Sánchez-Ortega I, Ciceri F, Sureda A. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60(11):1499-525. https://doi.org/10.1038/s41409-025-02701-3
31. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V, Dias Wickramanayake P. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol. 1999;78(9):418-25. https://doi.org/10.1007/s002770050541
32. Anžej Doma S, Sever M, Jakoš G, Podgornik H. FLAG/FLAG-Ida regimen in secondary and relapsed/ refractory acute myeloid leukemia—even in the era of new treatment modalities still a significant player. J. Clin Med. 2024;13(7):1842. https://doi.org/10.3390/jcm13071842
33. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728-40. https://doi.org/10.1056/nejmoa1902688
34. Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, Stein AS, Stone RM, Winer ES, Seet CS, Döhner H, Pollyea DA, McCloskey JK, Odenike O, Löwenberg B, Ossenkoppele GJ, Patel PA, Roshal M, Frattini MG, Lersch F, Franovic A, Nabhan S, Fan B, Choe S, Wang H, Wu B, Hua L, Almon C, Cooper M, Kantarjian HM, Tallman MS. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792-803. https://doi.org/10.1182/blood.2020007233
35. Sui J, Xu Z, Zhang L, Jiao Y, Bian R, Pan D, Yan X. Early replacement of re-induction therapy following failed intensive induction treatment enhances the therapeutic efficacy of newly diagnosed AML. Sci Rep. 2025;15(1):20022. https://doi.org/10.1038/s41598-025-04139-5
36. Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH. Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood Adv. 2021;5(24):5536-45. https://doi.org/10.1182/bloodadvances.2021005566
37. Jondreville L, Roos-Weil D, Uzunov M, Boussen I, Grenier A, Norol F, Morel V, Nguyen S, Souchet L. FLAMSAbusulfan-melphalan as a sequential conditioning regimen in HLA-matched or haploidentical hematopoietic stem cell transplantation for high-risk myeloid diseases. Transplant Cell Ther. 2021; 27 (11): 915.e1-e8. https://doi.org/10.1016/j.jtct.2021.07.018
38. Sackstein P, Williams A, Zemel R, Marks JA, Renteria AS, Rivero G. Transplant eligible and ineligible elderly patients with AML—a genomic approach and next generation questions. Biomedicines. 2024; 12 (5): 975. https://doi.org/10.3390/biomedicines12050975
39. Duarte FB, Garcia YDO, Hamerschlak N, Funke VAM, Moreira MCR, Paz AA, Filho JS, Astigarraga CC, da Silva RL, de Molla VC, Silvério A, Rocha VG, Feliciano JVP, Barros GMN, Colturato VAR, Nabhan SK, Farias JSH, Maia ACA, Atalla Â, Chiattone R, Macedo MCMA, Aranha MAF, Zogbi YAN, Lener D, Soares RDA, Scheinberg P, Calixto RF, Teixeira GM, Colella MP, Rodrigues CA, Simione AJ, Silva CC, Martin PJ, Flowers ME. Allogeneic hematopoietic cell transplantation in elderly patients in a Latin American country: analysis of 11 year of data from the Brazilian Registry SBTMO/CIBMTR. Transplant Cell Ther. 2025; 31(2): 79.e1-e9. https://doi.org/10.1016/j.jtct.2024.12.003
40. Wall SA, Devine S, Vasu S. The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years. Blood Rev. 2017;31(6):362-9. https://doi.org/10.1016/j.blre.2017.07.002
41. Lima YCSF, Duarte BA, Duarte Filho FB, Duarte IA, Duarte JVAD, Santos ACF, Colturato VAR, Souza MP, Simione AJ, Campos SEVC, Barroso F. Allogeneic hematopoietic stem cell transplantation in elderly patients in Brazil. J Bone Marrow Transplant Cell Ther. 2023;4(2):198. https://doi.org/10.46765/2675-374X.2023v4n2p198
42. Salas MQ, Alfaro Moya T, Pasic I, Baile González M, Acera Gómez M, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Sánchez Salinas A, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Cornago Navascues J, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Mussetti A, Lavilla E, Lopez-Marín J, Filaferro S, Basalobre P, Bento L, Law A, Viswabandya A, Michelis FV, Mattsson J, Alibhai SMH, Rovira M, Kim DDH, Sureda A, Kumar R. HCT Frailty Scale (HCTFS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort. eClinicalMedicine. 2026;91. https://doi.org/10.1016/j.eclinm.2025.103753
43. Sorror ML, Saber W, Logan B, Geller N, Bellach A, Kou J, Wood W, McCarty JM, Knight TG, Runaas L, Johnston L, Walston J, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus PH, Hogan WJ, Nadiminti K, Bhatt VR, Olin R, Maakaron J, Sobecks R, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS. Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704. Blood Adv. 2025;9(13):3268-80. https://doi.org/10.1182/bloodadvances.2025015793
44. Sarmento ALR. Montreal Cognitive Assessment (MoCA): versão experimental brasileira. Recife: Neuropsicologia Brasil; 2012.
45. Brasil. Ministério da Saúde. Portaria GM/MS n. 1.813, de 22 de julho de 2020. Diário Oficial da União. 2020.
46. Brasil. Ministério da Saúde. Portaria GM/MS n. 8.041, de 25 de setembro de 2025. Diário Oficial da União. 2025.
47. Duarte RF, Sánchez-Ortega I. HCT in elderly patients. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E (Eds.). The EBMT handbook: Hematopoietic cell transplantation and cellular therapies. 8th ed. Cham, Switzerland: Springer; 2024.
48. Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized phase III SIERRA trial of 131|-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed/refractory AML. J Clin Oncol. 2025;43(3):201-13. https://doi.org/10.1200/jco.23.02018
49. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525-36. https://doi.org/10.1016/s1470-2045(15)00200-4
50. Stölzel F, Stelljes M, Beelen DW, Markiewicz M, Reményi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socié G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlović J, Schild B, Khan I, Li X, Bethge W. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. Haematologica. 2026. https://doi.org/10.3324/haematol.2025.288770
51. Luo C, Zhang J, Huang X, Wu G, Huang Y, Ding Y, Huang Z, Song Q, Chen J, Li X, Xu S. The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and metaanalysis. Ann Hematol. 2025;104(12):6175-86. https://doi.org/10.1007/s00277-025-06342-w
52. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes long-term follow-up of the BMT CTN 0901 clinical trial. Transplant Cell Ther. 2021;27(6):483.e1-e6. https://doi.org/10.1016/j.jtct.2021.02.031
53. Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Blood Adv. 2025;9(20):5123-33. https://doi.org/10.1182/bloodadvances.2025016306
54. Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3,113 AML patients. Leukemia. 2023;37(5):1006-17. https://doi.org/10.1038/s41375-022-01738-3
55. Rodríguez-Arbolí E, Ferhat AT, Raiola AM, Morsink L, Blaise D, Versluis J, Sica S, Kwon M, López-Corral L, Nur E, Kulagin A, Bramanti S, Rovira M, Forcade E, Martino M, Vydra J, Piemontese S, Sanz J, Mohty M, Ciceri F. Late outcomes after posttransplant cyclophosphamide-based GVHD prophylaxis in patients with AML: an ALWP-EBMT study. Blood Neoplasia. 2026;3(2):100199. https://doi.org/10.1016/j.bneo.2026.100199
56. Gantner A, Labuhn S, Fürst D, Mannes S, Flossdorf S, Ayuk FA, Schroeder T, Stelljes M, Zeiser R, Dreger P, Eder M, Blau IW, Schetelig J, Brecht A, Burchert A, Edinger M, Wais V, Schrezenmeier H, Döhner H, Schmeller S, Fleischhauer K, Kröger N, Sala E, German Registry for Hematopoietic Stem Cell Transplantation and cell Therapy (DRST). Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies. Bone Marrow Transplant. 2026;61:694-701. https://doi.org/10.1038/s41409-026-02827-y
57. Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B. Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLADPB1 mismatches and post-transplant cyclophosphamide. Leukemia. 2026;40(5):934-45. https://doi.org/10.1038/s41375-026-02907-4
58. Ye Y, Labopin M, Yakoub-Agha I, Socié G, Blaise D, Gedde-Dahl T, Blau IW, Raiola AM, Byrne J, Daguindau E, Labussière-Wallet H, Huynh A, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Mohty M, Huang H, Ciceri F. Superior GVHD-free, relapse-free survival for haploidentical transplant with PTCy than matched unrelated donor for AML patients transplanted in second complete remission: a study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2025;100(10):1760-71. https://doi.org/10.1002/ajh.70008
59. Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socié G, Forcade E, Kröger N, Koc Y, Itäla-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8(10):2332-41. https://doi.org/10.1182/bloodadvances.2023012133
60. Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, Koc Y, Bramanti S, Kulagin A, Kwon M, Sica S, Sanz J, Brissot E, Nagler A, Ciceri F, Mohty M. Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Cancer. 2024;130(18):3123-36. https://doi.org/10.1002/cncr.35365
61. Byrne M, Savani BN, Mohty M, Nagler A. Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Exp Hematol. 2016;44(7):567-73. https://doi.org/10.1016/j.exphem.2016.04.005
62. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and highdose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-50. https://doi.org/10.1016/j.bbmt.2008.03.005
63. Campregher PV, Hamerschlak N, Colturato VA, Mauad MA, de Souza MP, Bouzas LF, Tavares R de C, Barros JC, Chiattone R, Paz A, Silla L, Vigorito AC, Miranda E, Funke VA, Flowers ME. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLAmatched related donor: retrospective analysis of 334 consecutive patients. Eur J Haematol. 2015;95(5): 421-5. https://doi.org/10.1111/ejh.12508
64. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O’Donnell P. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced intensity conditioning. Biol Blood Marrow Transplant. 2014;20(6):890-5. https://doi.org/10.1016/j.bbmt.2014.03.003
65. Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, Gorin NC, Giebel S, Mohty M, Savani BN, Nagler A. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51(11):1431-8. https://doi.org/10.1038/bmt.2016.167
66. Ciurea SO, Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019-24. https://doi.org/10.1097/tp.0b013e3181b9d710
67. Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, Bhatt NS, Arrieta Bolaños E, Bolon YT, Gadalla SM, Grunwald MR, Krem MM, Lee SJ, Marsh SGE, Martino R, Mehta PA, Milano F, Prestidge T, Saultz JN, Shaw BE, Spellman SR, Choe H, Shaffer BC. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025;9(14):3469-78. https://doi.org/10.1182/bloodadvances.2024014858
68. Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Gorin NC, Giebel S, Ciceri F, Nagler A. Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(11):1810-22. https://doi.org/10.3324/haematol.2017.176107
69. Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, Sizzano F, Chiesa L, Zino E, Lupo Stanghellini MT, Assanelli A, Carrabba MG, Marktel S, Marcatti M, Bordignon C, Corti C, Bernardi M, Peccatori J, Bonini C, Fleischhauer K, Ciceri F, Vago L. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29(5):1143-52. https://doi.org/10.1038/leu.2014.314
70. Chakrabarty JLH, Rubinger M, Le-Rademacher J, Wang HL, Grigg A, Selby GB, Szer J, Rowe JM, Weisdorf DJ, Tallman MS. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant. 2014; 20(7): 1021-5. https://doi.org/10.1016/j.bbmt.2014.03.025
71. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3 –internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002. https://doi.org/10.1200/jco.19.03345
72. Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim DDH, Hernandez D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180-9. https://doi.org/10.1038/s41409-020-01153-1
73. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, Thiede C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012; 26(3):381-9. https://doi.org/10.1038/leu.2011.234
74. Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526-37. https://doi.org/10.1056/NEJMoa2004444
75. Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/ MORPHO Study Investigators. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766-75. https://doi.org/10.1200/jco.23.02474
76. Lloret-Madrid P, Chorão P, Guerreiro M, Montesinos P. CAR-T cell therapy for acute myeloid leukemia: where do we stand now? Curr Oncol. 2025;32(6):322. https://doi.org/10.3390/curroncol32060322
77. Damiani D, Tiribelli M. CAR-T cells in acute myeloid leukemia: where do we stand? Biomedicines. 2024; 12(6):1194. https://doi.org/10.3390/biomedicines12061194
78. Cummins K, Gill S. Chimeric antigen receptor T cells in acute myeloid leukemia. Hematol Oncol Clin North Am. 2023;37(6):1125-47. https://doi.org/10.1016/j.hoc.2023.06.004
79. Wang X, Zhang Y, Xue S. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia. Ann Hematol. 2024;103(6):1843-57. https://doi.org/10.1007/s00277-023-05601-y
80. Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J Hematol. 2024;120(4):455-66. https://doi.org/10.1007/s12185-024-03809-w
81. Sauer T, Rooney CM. Current challenges for CAR T-cell therapy of acute myeloid leukemia. Transfusion. 2019;59(4):1171-3. https://doi.org/10.1111/trf.15199
82. Hederih J, Patrick J, Gannon I, Rampotas A, Roddie C, Sellar R. CAR cellular therapies for acute myeloid leukemia: current landscape and future directions. Immunotherapy. 2026;18(7):615-32. https://doi.org/10.1080/1750743X.2026.2689849
83. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100. https://doi.org/10.1126/science.1068440
84. McCurdy SR, Radojcic V, Tsai HL, Vulic A, Thompson E, Ivcevic S, Kanakry CG, Powell JD, Lohman B, Adom D, Paczesny S, Cooke KR, Jones RJ, Varadhan R, Symons HJ, Luznik L. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139(4):608-23. https://doi.org/10.1182/blood.2021013054
85. Silla L. Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunother Adv. 2023;3(1):ltac024. https://doi.org/10.1093/immadv/ltac024
86. Cichocki F, Felices M, Matson AW, Lee MJ, Miller JS. Can natural killer cells cure leukemia? Leukemia. 2026;40(8):1600-3. https://doi.org/10.1038/s41375-026-02992-5
87. Wethington D, Ahmad S, Potempa M, Giuliani G, Aguilar OA, Poudel M, Grassmann S, Stewart W, Adams NM, Sun JC, Lanier LL, Das J. Clonal stochasticity in early NK cell response to mouse cytomegalovirus is generated by mature subsets of varying proliferative ability. bioRxiv [Preprint]. 2025:2023.09.07.556760. https://doi.org/10.1101/2023.09.07.556760
88. Gurney M, O’Dwyer M. Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia. Cancers (Basel). 2021;13(7):1568. https://doi.org/10.3390/cancers13071568
89. Rana S, Thomas L, Kirkham AM, Shorr R, Visram A, Maganti H, Seftel M, Allan DS. CAR-NK cells to treat patients with cancer: a systematic scoping review of published studies and registered clinical trials. Cytotherapy. 2025;27(10):1179-89. https://doi.org/10.1016/j.jcyt.2025.06.006
90. Bahramloo M, Shahabi SA, Kalarestaghi H, Rafat A, Mazloumi Z, Samimifar A, Asl KD. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage. Biomed Pharmacother. 2024;177:117024. https://doi.org/10.1016/j.biopha.2024.117024
91. Mansour AG, Teng KY, Li Z, Zhu Z, Chen H, Tian L, Ali A, Zhang J, Lu T, Ma S, Lin CM, Caligiuri MA, Yu J. Off the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia. Blood Adv. 2023;7(20):6225-39. https://doi.org/10.1182/bloodadvances.2022007405
92. Dong H, Ham JD, Hu G, Xie G, Vergara J, Liang Y, Ali A, Tarannum M, Donner H, Baginska J, Abdulhamid Y, Dinh K, Soiffer RJ, Ritz J, Glimcher LH, Chen J, Romee R. Memory-like NK cells armed with a neoepitopespecific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(25):e2122379119. https://doi.org/10.1073/pnas.2122379119
93. Klaihmon P, Luanpitpong S, Kang X, Issaragrisil S. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell Int. 2023;23(1):297. https://doi.org/10.1186/s12935-023-03153-9
94. Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J Immunother Cancer. 2021;9(12): e003894. https://doi.org/10.1136/jitc-2021-003894
95. Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A. Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123. Viruses. 2021;13(7):1365. https://doi.org/10.3390/v13071365
96. Wang Y, Yu Y, Wang S, Qu J, Song Y. From innate immunity to precision cancer therapy: the clinical advancement of NK cell therapy. Int Immunopharmacol. 2026;174:116373. https://doi.org/10.1016/j.intimp.2026.116373
97. Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, Alzubi J, Särchen V, Vogler M, Rasheed HM, Jung BA, Wolf S, Bhayadia R, Oellerich T, Klusmann JH, Penack O, Möker N, Cathomen T, Rieger MA, Imkeller K, Ullrich E. CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439. https://doi.org/10.1038/s41467-024-52388-1
98. Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L. Synergizing hypomethylating agents with off-theshelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. Leukemia. 2026;40(5):880-93. https://doi.org/10.1038/s41375-026-02930-5
99. Li YR, Chen Y, Yang L. Exploring CAR cell therapies beyond CAR-T for myeloid malignancies. J Biomed Sci. 2026;33(1):60. https://doi.org/10.1186/s12929-026-01265-8
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Mariana Pereira, Maura Rosane Valério Ikoma-Colturato, Vaneuza Araujo Funke, Beatriz Stela Gomes de Souza Pitombeira, Eduardo José de Alencar Paton, Adriano Arantes, Karine Sampaio Nunes Barroso, Miriam Perlingeiro Beltrame, Gustavo Bettarello, Camila de Pádua Coelho Hugo, Tharsis Cardoso Ferreira dos Santos, Felipe Magalhães Furtado, Elizabeth Xisto Souto, Fernando Barroso Duarte, Lucia Silla
This work is licensed under a Creative Commons Attribution 4.0 International License.
